Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerecor Inc. stock logo
CERC
Cerecor
$10.92
-1.6%
$2.60
$1.98
$4.50
$1.05B1.441.27 million shs15,370 shs
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$7.47
+4.3%
$6.49
$4.00
$8.69
$94.87M0.838,014 shs28,450 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.39
$1.41
$1.26
$2.66
$68.40M0.745,843 shs2,855 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerecor Inc. stock logo
CERC
Cerecor
+15.75%+2.59%-4.56%+159.95%+226.47%
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
LifeVantage Co. stock logo
LFVN
LifeVantage
-0.28%+2.29%+6.87%+2.58%+57.71%
MediciNova, Inc. stock logo
MNOV
MediciNova
+1.46%-6.08%0.00%+2.96%-36.24%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
2.0369 of 5 stars
0.03.01.72.72.71.71.3
MediciNova, Inc. stock logo
MNOV
MediciNova
0.2612 of 5 stars
0.04.00.00.02.30.80.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M156.48N/AN/A$0.22 per share49.64
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
LifeVantage Co. stock logo
LFVN
LifeVantage
$213.40M0.44$0.54 per share13.85$2.11 per share3.54
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M68.40N/AN/A$1.22 per share1.14

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2826.68N/A1.75%27.02%12.42%8/26/2024 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$8.56M-$0.17N/AN/AN/AN/A-13.35%-12.64%8/14/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.141.87%N/A50.00%2 Years
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A

Latest LFVN, MNOV, CERC, and CHMA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.042.44%5/31/20245/31/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.01
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
19.07
19.07

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%

Insider Ownership

CompanyInsider Ownership
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Chiasma, Inc. stock logo
CHMA
Chiasma
8.30%
LifeVantage Co. stock logo
LFVN
LifeVantage
6.76%
MediciNova, Inc. stock logo
MNOV
MediciNova
14.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.70 million11.84 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1349.05 million41.74 millionOptionable

LFVN, MNOV, CERC, and CHMA Headlines

Recent News About These Companies

StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV)
MediciNova: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cerecor logo

Cerecor

NASDAQ:CERC
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Chiasma logo

Chiasma

NASDAQ:CHMA
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
MediciNova logo

MediciNova

NASDAQ:MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.